Authors
Dr. Rosenbaum, professor, Medicine and Ophthalmology, Joint Professor, Cell and Developmental Biology, Casey Eye Institute, Oregon Health & Science University, Portland.
Odden, an ophthalmology resident at the University of Pittsburgh Medical Center in Pennsylvania, has no financial disclosures related to this content.
e:oddenjl@upmc.edu
Dr. Handza is the Chief Medical officer at Nextech.
He is a faculty member of the Nurse Anesthesia Program, College of Applied Studies, Florida State University, Panama City, Florida, and a practicing CRNA at Jackson Anesthesia Associates, Marianna, Florida.
UnCommon Sense, Long Beach CA
An specializes in glaucoma treatment at the Mason Eye Clinic at the University of Missouri in Columbia.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
One day, three approvals: FDA expands options for ocular redness, thyroid eye disease, and presbyopia
2
Duravyu misses wet AMD end point again as EyePoint pivots to DME
3
The Retina TL;DR with Dr. Weng: Thriving in fellowship with Amer Alsoudi, MD, and Monia Reding, MD
4
A vascular link: erectile dysfunction may signal glaucoma risk in men
5